ArticleHealth science reports2025
Trends and Developments in Vulvar Lichen Sclerosus Research.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the prevalence of vulvar lichen sclerosus (VLS) as a chronic skin disease in clinical settings, there is a notable absence of a comprehensive bibliometric analysis summarizing the existing literature on this topic. The aim of this study is to offer clinicians, researchers, and other interested parties an up-to-date overview of the research status and emerging trends in VLS through the use of bibliometric analysis. Methods: The present research employed a thorough examination of the Web of Science Core Collection to identify publications pertaining to VLS within the time frame of January 1, 1994, to December 31, 2023. A total of 1698 publications were scrutinized utilizing Microsoft Excel software and various visualization tools, including CiteSpace, VOSviewer, and Pajek, to discern specific characteristics. Results: The current research encompassed a total of 1,698 articles pertaining to VLS. The analysis of citation bursts and co-citation patterns has revealed a high level of confidence in the effectiveness and safety of topical corticosteroids for the treatment of VLS, establishing them as the preferred primary treatment for this condition. Since 2018, there has been a significant increase in VLS publications, with the United States and United Kingdom emerging as leading contributors. Research has moved from examining past pathological changes like "epidermal atrophy" to focusing on "long-term treatment management," and improving "quality of life". The exact mechanism of VLS remains unclear, but it is linked to cytokine immune regulation, oxidative stress, and potential epigenetic changes or genetic mutations in susceptible individuals. It could also develop into vulvar squamous cell carcinoma. Conclusions: Institutions are expected to allocate more resources for VLS prevention and long-term management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.